Abcam, ab273857, Human MAGEA4 knockout A-431 cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
MAGEA4 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9; X = 2 bp deletion, 1 bp insertion; Frameshift: 99%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A-431,
Species or organism:Human,
Tissue:Skin,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 2 bp deletion, 1 bp insertion; Frameshift: 99%,
Disease:Epidermoid Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MAGEA4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAGEA4 also known as MAGE-A4 is part of the melanoma-associated antigen family. This protein is encoded by the MAGEA4 gene and is characterized by a molecular mass of approximately 42 kDa. Its expression is limited to certain tissues including the testis and is often silent in normal somatic tissues. However MAGEA4 is frequently found in various types of tumors making it a target of interest for cancer research and therapy.
Biological function summary
MAGEA4 participates in cellular processes related to cancer progression. Although not part of a multi-protein complex its presence in tumorous tissues suggests a role in modulating cellular mechanisms that favor tumor survival and proliferation. MAGEA4 does not directly interact with other proteins but might affect cellular pathways indirectly contributing to oncogenesis.
Pathways
MAGEA4 influences several cellular mechanisms that are related to cancer development. While it is not a central player in major biological pathways its function relates to processes affecting cell cycle regulation and apoptosis. This connection was observed in studies showing interactions with other cancer-related proteins like p53 suggesting that MAGEA4 can modify responses to apoptotic signals and may interact with or affect the TP53 pathway.
MAGEA4 is prominently linked to various cancers including melanomas and carcinomas such as lung cancer. Its frequent expression in tumor cells but not in normal tissues makes MAGEA4 a target for cancer immunotherapy. Additionally studies have shown that MAGEA4 may interfere with the immune system's ability to detect and destroy cancerous cells partly due to interactions with proteins like CTLA-4 further emphasizing its potential as a therapeutic target in oncology.